Summary

The 7 major retinitis pigmentosa markets reached a value of US$ 9.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 17.1 Billion by 2034, exhibiting a growth rate (CAGR) of 5.99% during 2024-2034.

The retinitis pigmentosa market has been comprehensively analyzed in IMARC's new report titled "Retinitis Pigmentosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Retinitis pigmentosa is a group of genetic eye disorders that primarily affect the retina, which is the light-sensitive tissue at the back of the eye. It typically causes progressive degeneration of the photoreceptor cells in the retina, leading to vision loss and, eventually, blindness. The disorder affects rods and cones, the two types of photoreceptor cells responsible for vision in low-light and bright-light conditions, respectively. The ailment typically causes night blindness, followed by tunnel vision and loss of central vision. Various other symptoms include difficulty distinguishing colors, glare sensitivity, and reduced visual acuity. As the disease progresses, it can lead to more severe visual impairment. The ailment is typically diagnosed through a comprehensive eye examination that comprises a visual acuity test, a visual field test, an electroretinogram (ERG), and genetic testing to identify any known mutations associated with the disease. During the examination, an eye care professional will evaluate the health of the retina and look for characteristic changes, such as the presence of pigmentation and the thinning of blood vessels. They may also perform additional tests to assess visual function, such as color vision testing and contrast sensitivity testing.

The rising cases of mutations in various genes that are involved in the function and maintenance of the retina are primarily driving the retinitis pigmentosa market. Additionally, the increasing prevalence of several triggering factors, such as genetic predisposition, certain medical conditions like Usher syndrome, exposure to environmental toxins, etc., is also propelling the market growth. Besides this, the widespread adoption of antioxidant therapy that involves taking supplements, including vitamin C, vitamin E, coenzyme Q10, etc., to reduce the levels of oxidative stress in the retina is creating a positive outlook for the market. Moreover, the emerging popularity of retinal prostheses, which use electrical stimulation to activate the remaining cells in the retina, allowing patients to distinguish between light and dark, is acting as another significant growth-inducing factor. Apart from this, the rising usage of fundus photography in diagnosing the ailment by detecting changes in the appearance of the retina, such as the presence of bone spicules, is also augmenting the market growth. Furthermore, the escalating demand for RNA therapy to slow or halt the progression of the condition, as well as improve visual function and quality of life for affected individuals, is expected to drive the retinitis pigmentosa market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the retinitis pigmentosa market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for retinitis pigmentosa and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the retinitis pigmentosa market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the retinitis pigmentosa market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the retinitis pigmentosa market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current retinitis pigmentosa marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the retinitis pigmentosa market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the retinitis pigmentosa market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the retinitis pigmentosa market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of retinitis pigmentosa across the seven major markets?
What is the number of prevalent cases (2018-2034) of retinitis pigmentosa by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of retinitis pigmentosa by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with retinitis pigmentosa across the seven major markets?
What is the size of the retinitis pigmentosa patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of retinitis pigmentosa?
What will be the growth rate of patients across the seven major markets?

Retinitis Pigmentosa: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for retinitis pigmentosa drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the retinitis pigmentosa market?
What are the key regulatory events related to the retinitis pigmentosa market?
What is the structure of clinical trial landscape by status related to the retinitis pigmentosa market?
What is the structure of clinical trial landscape by phase related to the retinitis pigmentosa market?
What is the structure of clinical trial landscape by route of administration related to the retinitis pigmentosa market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Retinitis Pigmentosa - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Retinitis Pigmentosa - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Retinitis Pigmentosa - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Retinitis Pigmentosa - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Retinitis Pigmentosa - Unmet Needs

10 Retinitis Pigmentosa - Key Endpoints of Treatment

11 Retinitis Pigmentosa - Marketed Products
11.1 List of Retinitis Pigmentosa Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Retinitis Pigmentosa - Pipeline Drugs
12.1 List of Retinitis Pigmentosa Pipeline Drugs Across the Top 7 Markets
12.1.1 AAV2/5 RPGR - Janssen Pharmaceuticals/MeiraGTx
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 EA2353 - Endogena Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 hRPC - ReNeuron
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 jCell - jCyte
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ADX-2191 - Aldeyra Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Retinitis Pigmentosa - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Retinitis Pigmentosa – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Retinitis Pigmentosa - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Retinitis Pigmentosa - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Retinitis Pigmentosa - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Retinitis Pigmentosa - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Retinitis Pigmentosa - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Retinitis Pigmentosa - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Retinitis Pigmentosa - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Retinitis Pigmentosa - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Retinitis Pigmentosa - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Retinitis Pigmentosa - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Retinitis Pigmentosa - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Retinitis Pigmentosa - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Retinitis Pigmentosa - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Retinitis Pigmentosa - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Retinitis Pigmentosa - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Retinitis Pigmentosa - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Retinitis Pigmentosa - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Retinitis Pigmentosa - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Retinitis Pigmentosa - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Retinitis Pigmentosa - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Retinitis Pigmentosa - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Retinitis Pigmentosa - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Retinitis Pigmentosa - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Retinitis Pigmentosa - Access and Reimbursement Overview

16 Retinitis Pigmentosa - Recent Events and Inputs From Key Opinion Leaders

17 Retinitis Pigmentosa Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Retinitis Pigmentosa Market – Strategic Recommendations

19 Appendix